Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Detemir

PreclinicalSmall molecule

Detemir is one of 77 small molecule programs targeting Obesity. It is currently in Preclinical.

2

Indications

13

Total Trials

1

Active Trials

76

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

Type 1 DiabetesActive, not recruiting

ObesityPreclinical

Active, not recruiting

Type 1 DiabetesPreclinical

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Cagrisema

Zenagamtide

Eloralintide

Belantamab Mafodotin-Blmf

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Avapro

Amidate

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/AActive, not recruiting

Obesity

NCT01239550

Clinical

Trials by Indication[1]

Type 2 Diabetes3 trials

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01966978·157 enrolled

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00494013·442 enrolled

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

Completed·DDiabetes Care Center·N/A·NCT00457093·35 enrolled

Diagnosis1 trial

Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis

Unknown status·KKarolinska Institutet·Phase 4·NCT01271517·120 enrolled

Obesity1 trial

Insulin Detemir in Obesity Management

Active, not recruiting·VVanderbilt University·N/A·NCT01239550·240 enrolled

Effectiveness1 trial

Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Completed·UUniversity of Colorado, Denver·N/A·NCT01186003·30 enrolled

Hypoglycemia1 trial

Hypoglycemia Counterregulation and Symptom Perception With Insulin Detemir

Terminated·UUniversity Hospital Tuebingen·Phase 4·NCT00490893·12 enrolled

3 more indications

Open Heart Surgery1 trial

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir

Completed·OOhio State University·Phase 4·NCT00717288·82 enrolled

Type 1 Diabetes1 trial

Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes

Completed·UUniversity of Calgary·N/A·NCT00522210·18 enrolled

Unspecified4 trials

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Completed·UUniversity of Padova·Phase 4·NCT00699686·50 enrolled

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Completed·UUniversity of Aarhus·Phase 3·NCT01461616·19 enrolled

Hospital In-Patient Insulin Study

Terminated·—·Phase 4·NCT00135070·41 enrolled

Show 1 more trial

Detemir Energy Expenditure Study

Completed·UUniversity of Surrey·Phase 4·NCT00788840·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Detemir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Detemir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Detemir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Eli Lilly

Related News